Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment
Autor: | Ryosuke Ochiai, Kentaro Hayashi, Hiroshi Yamamoto, Risa Fujii, Naomi Saichi, Hiroki Shinchi, Tsuyoshi Ishida, Takeshi Honda, Tetsuo Shimizu, Noriyuki Matsutani, Nobuhiko Seki, Masafumi Kawamura, Koji Ueda |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Cancer Science. 113:3960-3971 |
ISSN: | 1349-7006 1347-9032 |
DOI: | 10.1111/cas.15512 |
Popis: | To identify liquid biomarkers that predict clinical outcomes of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), we enrolled patients with EGFR gene mutation-positive non-small-cell lung cancer who were intended to receive gefitinib treatment. Using plasma samples obtained prior to gefitinib treatment from 12 enrolled patients, we performed comprehensive proteomic analysis of plasma exosomes to explore proteins correlating with tumor reduction rate (TRR), progression-free survival (PFS), or overall survival (OS). Of the detected 1769 proteins, 119, 130, or 119 proteins demonstrated a strong correlation (|r| 0.5) with TRR, PFS, or OS, respectively. Interestingly, 34 (29%), 41 (32%), or 27 (23%) of them, respectively, were functionally involved in the regulation of the immune response. CD8α chain was consistently listed as a molecule positively correlated with PFS and OS, suggesting that the long-lasting effects of gefitinib may be due to the antitumor effects of CD8 |
Databáze: | OpenAIRE |
Externí odkaz: |